



**NMS Labs**

**CONFIDENTIAL**

200 Welsh Road, Horsham, PA 19044-2208  
Phone: (215) 657-4900 Fax: (215) 657-2972  
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

**Demo Report**

**Report Issued** 04/21/2022 18:36  
**Last Report Issued** 03/21/2017 08:18

**88888**  
Clinical Example Report  
Attn: Example Reports  
200 Welsh Road  
Horsham, PA 19044

**Patient Name** 4025SP  
**Patient ID** 4025SP  
**Chain** 17000517  
**DOB** Not Given  
**Sex** Not Given  
**Workorder** 17000517  
**Received** 03/21/2017

**Lab ID** 17000517-001  
**Matrix** Serum or Plasma  
**Patient Name** 4025SP  
**Patient ID** 4025SP  
**Container Type** Clear vial

**Collect Dt/Tm** Not Given  
**Source** Not Given

**Approx Vol/Weight** Not Given

**Receipt Notes** None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

**4025SP Ezogabine and Metabolite, Serum/Plasma**

Analysis by High Performance Liquid Chromatography/  
Tandem Mass Spectrometry (LC-MS/MS)

Ezogabine	None Detected	ng/mL	40	
-----------	---------------	-------	----	--

Synonym(s): Potiga; Retigabine; Trobalt

The optimized effective dose is 600 to 1200 mg daily. Ezogabine exhibits a linear pharmacokinetic profile between 600 - 1200 mg. Ezogabine is rapidly absorbed with a median time to maximum blood levels between 30 minutes to 2 hours. Patients titrated from 200 - 700 mg daily over a 15 day period had mean maximum plasma concentrations (Cmax +/- SD) of 1593 +/- 198 ng/mL.

Administration of ezogabine at therapeutic doses may increase digoxin serum concentrations. Patients using ezogabine and digoxin should also have their digoxin levels monitored.

N-Acetyl Ezogabine	None Detected	ng/mL	40	
--------------------	---------------	-------	----	--

Synonym(s): Ezogabine Metabolite; AWD21-360

Results for sample 17000517-001 are continued on next page



### NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208  
Phone: (215) 657-4900 Fax: (215) 657-2972  
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

**Lab ID** 17000517-001  
**Matrix** Serum or Plasma  
**Patient Name** 4025SP  
**Patient ID** 4025SP

**Collect Dt/Tm** Not Given  
**Source** Not Given

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

Formed by N-acetylation of ezogabine and is pharmacologically less active as compared to ezogabine. Patients titrated from 200 - 700 mg daily over a 15 day period had mean maximum plasma concentrations of (Cmax +/- SD) 874 +/- 75 ng/mL.

Administration of ezogabine at therapeutic doses may increase digoxin serum concentrations. Patients using ezogabine and digoxin should also have their digoxin levels monitored.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.